Thrombotic thrombocytopenic purpura associated with cerebral SLE. by McHenry, M. et al.
The Ulster Medical Journal, Volume 72, No. 1, pp. 52-54, May 2003.
Case Report
Thrombotic thrombocytopenic purpura associated with
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A case ofthrombotic thrombocytopenic purpura
in apatientwith arecentflare ofcerebral lupus is
presented. The patientpresented with neurologic
symptoms, pyrexia, thrombocytopenia and
leucocytosis. Following initial investigation,
imaging of brain and negative microbiology, a
diagnosis of cerebral lupus was made and
appropriately treated. Afterastableperiodoftwo
weeks, deterioration in clinical status,
haematology and renal indices, a diagnosis of
thromboticthrombocytopenicpurpura(TTP)was
made and treated. The two diagnoses presenting
together are briefly discussed.
CASE REPORT: A 74-year-old Caucasian lady
presented with a 3-day history of headache,
drowsiness, vomiting and generalised aches and
pains. She had a 2-year history ofsystemic lupus
erythematosus (SLE). Herdiseasewascontrolled
on prednisolone 5mg daily, and hydroxy-
chloroquine 200mg daily. On this regimen she
had been stable for two years. She had recently
been diagnosed with hypertension, and was on
bendrofluazide 2.5mg daily, and atenolol 50mg
daily.
On initial examination she was alert and
orientated, with a temperature of 38.2°C. The
bloodpressure was 160/78mmHgwithnopostural
drop. There was no neck stiffness, photophobia,
orfocal signs ofinfection. There was noevidence
of cutaneous vasculitis, mouth ulceration, or
synovitis.
Investigationsrevealed: Hb-11.7g/dl(11.5-16.5g/
dl), platelets 115x 109/1 (150-400), WCC-
19.2x109/1 (neut-16.38), totalprotein-69g/L(60-
80g/L), serumelectrolytesandureaandcreatinine
were normal. Theerythrocyte sedimentation rate
(ESR) was 44mm/hr, C reactive protein (CRP)
87mg/i (<lSmg/L), C3 0.77g/L (0.88-2.Olg/L)
and C4 0.lOg/L (0.16-0.47g/L). MSSU was
negative. Bloodcultures werenegative including
fungal, acidfastandviralcultures. Anticardiolipin
and lupus coagulant were within normal limits.
Chest X-ray was normal.
A CT scan ofbrain was normal, lumbarpuncture
revealed an elevated WCC 196/mm3 (50%
lymphocytes and 50% neutrophils), with an
elevated protein count 0.99g/L (0.2-0.4g/L),
glucose 1.4mmol/L (2.4-4.4mmol/L). Serum
glucosewas4.9mmol/L. CSFculturewasnegative
including acidfastfungal andviralcultures. PCR
and antigen levels for meningococcus were
negative.
The patient developed an absence seizure with
transientright-sidedweaknessfollowedbyafocal
seizure progressing to a generalised tonic-clonic
seizure. GlasgowComaScale(GCS)postseizure
was9/15.HerGCSimproved;howeverthepatient
remainedconfusedandcognitivelyimpaired,with
brisk reflexes and an extensor leftplantar reflex.
Magnetic resonance imaging (MRI) of brain
revealed mild to moderate degree of cerebral
parenchymalloss.Widescatteredill-definedhigh
signal intensity was noted in the white matter,
which was thought to representgliotic ischaemic
changes.
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A clinical diagnosis ofcerebral lupus was made.
The patient was given intravenous
methylprednisolone, Ig for 3 consecutive days,
then commenced on oral prednisolone daily and
she received pulse cyclophosphamide 500mg
intravenouslyweekly.Therewasanimprovement
inhercognitiveimpairmentandclinicalcondition.
After a stable period of two weeks, her clinical
conditiondeclinedwithdeteriorationincognitive
function. Her platelet count fell to 41 x 109/l and
Hb to 7.4g/dl, (normal MCV and MCH). On 24
hour urine collection she had 1.13g proteinuria.
Total bilirubin and lactate dehydrogenase were
mildlyelevated. DirectCoombstestwasnegative.
Reticulocyte count was 3.5%. Prothrombin time
andfibrinogen were normal. Bloodfilmrevealed
fragmentedredbloodcells.Bonemarrowaspirate
did not detect a monoclonal T-cell or B-cell
population. There were some megakaryocytes
present but they were not particularly plentiful.
Somehistiocyteswerealsopresent. Onperipheral
blood analysis there was no evidence ofplatelet
associated immunoglobulin detected by flow
cytometry.
In view of the fragmented red cells, clinical
deterioration and renal involvement a diagnosis
of thrombotic thrombocytopenic purpura (TTP)
was made. Plasmapheresis was instituted. The
patient responded rapidly after three therapies
with an increase in platelet count, improvement
in renal function and cognition.
DISCUSSION
Systemic lupus erythematosus is a chronic often
life-long, autoimmune disorder associated with
multi-organ involvement. CNS lupus is one of
thefourmostcommon causes ofdeath in SLE (7-
13%,' the other three being infection, cardiac
involvement and lupus nephritis. The diagnosis
of cerebral lupus can be very difficult. In the
setting of a lupus patient with pyrexia, a raised
white cell count, and immunosuppressed, it is
vital toexclude infection. Fever occurs in 90% of
patients with active SLE. Cerebral lupus can
present with either diffuse or focal signs. In
diffuse disease symptoms and/or signs such as
intractable headaches, seizures, aseptic
meningitis, psychiatric disease and coma may
occur. In focal disease, manifestations include
focal seizures, stroke syndromes, and movement
disorders and transverse myelitis. There may be
signs of active lupus disease elsewhere such as
alopecia, vasculitic rash, mouth ulceration or
arthritis. When the disease is active there can be
immunologic abnormalities: marked
inflammatory response; low levels of serum
complement; and elevation of anti-nuclear
antibodies. Risk factors for the development of
CNS disease in a lupus patient are not clearly
defined. One study by Karassa et all tried to
define these risks. In the study the most frequent
neuropsychiatric SLE (NPSLE) syndromes were
cerebrovascular disease (28%), seizures (25%),
acute confusional states (19%), and psychosis
(9%). 3-8% of patients presented with a
combination of two or more symptoms. It was
suggested that vasculitis, thrombocytopenia and
anti-phospholipid syndrome features correlated
with CNS involvement. It was negatively
associated with articular features and discoid
rash. Normal levels ofdsDNA were also seen in
activeCNS disease, butantiLaantibodiesaswell
as low level ofcomplements especially C4 were
seemingly strongly associated withNPSLE. TTP
has rarely been seen in association with SLE, but
is recognised in the literature andthe two disease
processes were first described together in 1939.
TheabilitytodiagnoseTTPasaseparateprocess,
in the setting of SLE is challenging, as TTP has
no specific diagnostic test and also because TTP
shares, in common with SLE, clinical signs and
features such as fever, renal abnormalities,
neurological deficit, thrombocytopenia, and
haemolytic anaemia.
The pathogenesis ofthe two disease processes is
different. Microangiopathic haemolytic anaemia
is rarely seen in SLE, and only if the disease is
very active, with severe vasculitis. On the other
hand, the serological abnormalities seen in SLE
are not seen in TTP.2 Thrombocytopenia and
haemolytic anaemia in TTP is therefore usually
due to a microangiopathic process, whereas in
SLE it is usually due to an immune mediated
process.3
TTPhasbeenassociatedwithSLEinthreedistinct
populations.4 These are TTP presenting
subsequent (group 1), preceding (group 2), or
concomitantly (group 3) to SLE. The most
common presentation with SLE is with group 1
and the leastcommon with group 3. TTP can also
be associated with SLE whether it is active or
inactive.4
TheincidenceofTTPandSLEremainsunknown.
In 1994 it was reported by Bray et al to be as low
as 0.5 %.5 Caramaschi et al in 19983 quoted a
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frequency of 2-3%. The large autopsy report by
Petz etalin 1977 reported a5% incidence ofTTP
in SLE patients.
The development of TTP associated with SLE
suggests that the two processes have features in
common. In both diseases, direct endothelial
injury by autoantibodies, platelet abnormalities,
and disorders of fibrinolysis can occur. Yet the
fact that TTP can develop in quiescent or active
SLE suggests thatthe two are separateprocesses.
Treatment strategies for TTP were dramatically
improved with the introduction of plasma
exchange. Indeed it has been suggested that
survivalofthepatientcorrelates withtherapidity
of diagnosis, and the use of plasma exchange
ratherthanactualdiseaseactivity.2'4Sinceplasma
exchange is considered the treatment of choice
for TTP and is thought to be of some benefit in
vasculitis, delay in its usage until a definitive
diagnosis is reached may increase morbidity and
mortality.5 This case highlights the difficulty in
treating SLE patients. It emphasises the
importance of early diagnosis of TTP in a SLE
patient in order to combine plasmaexchange and
immunosuppressanttherapy, whichundoubtedly
improves outcome.
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